Ordering
Available Variants10 mg
CHA.42247-10mg
Price
€112.80
Available – Dispatch in 14 days
50 mg
CHA.42247-50mg
Price
€384.80
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.42247-10mg | €112.80 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.42247-50mg | €384.80 |
≥98% (HPLC), Class III antiarrhythmic agent, solid
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C20H36N2O3S · 0.5C4H4O4 |
|---|---|
| CAS Number | 122647-32-9 |
| Molecular Weight | 442.61 |
| UNSPSC Code | 12352200 |
| PubChem Substance ID | 329815470 |
| NACRES | NA.77 |
| MDL number | MFCD01715410 |
| Assay | ≥98% (HPLC) |
| Form | solid |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS08
GHS07
  GHS08,GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302,H361d |
| pcodes | P202 - P264 - P270 - P280 - P301 + P312 - P308 + P313 |
| Hazard Classifications | Acute Tox. 4 Oral - Repr. 2 |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 1 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Ibutilide hemifumarate salt, with a CAS number of 122647-32-9, is a pharmaceutical compound utilized in the management of certain cardiac arrhythmias. It functions as a class III antiarrhythmic agent, exerting its effects by prolonging the action potential duration in cardiac myocytes, which in turn increases the effective refractory period. This mechanism of action helps to prevent the recurrence of arrhythmias such as atrial fibrillation and flutter. Ibutilide hemifumarate salt is administered intravenously, allowing for rapid onset of action, and its efficacy has been demonstrated in various clinical trials. As with other antiarrhythmic agents, the use of ibutilide hemifumarate salt requires careful patient selection and monitoring due to the potential for proarrhythmic effects and other adverse reactions. Its therapeutic utility is well-established in the field of cardiology for the acute conversion of arrhythmias.
